Celivarone fumarate | 752253-75-1

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: Celivarone fumarate
• 英文别名: isopropyl 2-n-butyl-3-[4-[3-(dibutylamino)propyl]benzoyl]-1-benzofuran-5-carboxylate fumarate；isopropyl 2-butyl-3-[4-[3-(dibutylamino)propyl]benzoyl]-1-benzofuran-5-carboxylate fumarate；(E)-but-2-enedioic acid;propan-2-yl 2-butyl-3-[4-[3-(dibutylamino)propyl]benzoyl]-1-benzofuran-5-carboxylate
• CAS: 752253-75-1
• 化学式: C₄H₄O₄*C₃₄H₄₇NO₄
• 分子量: 649.825
• InChiKey: OJGUHVXJDZPQSK-WLHGVMLRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  8.12
• 重原子数：
  47
• 可旋转键数：
  20
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  134
• 氢给体数：
  2
• 氢受体数：
  9

反应信息

• 作为产物：
  描述：

  isopropyl 2-butyl-3-{4-[3-(dibutylamino)propyl]benzoyl}-1-benzofuran-5-carboxylate 在 富马酸 作用下， 以 丙酮 为溶剂， 生成 Celivarone fumarate
  参考文献：
  名称：

  Aminoalkoxybenzoyl-benzofuran or benzothiophene derivatives, method of preparing same and compositions containing same

  摘要：

  苯并噻吩及其相关化合物的化学式（1），其中A、B、Z分别为—CH，—CR4或N—；X为—S—，—O—，—NH—，—NR2，—CH2—CH2—，CH2—CH2—CH2—，—CH2—O—，—OCH2—，—CH2—S—，—CO—，—SCH2—，—NCR2—或R2CN—；Y为可选择地取代的苯基，烷基，环烷基，环烯基，杂环或双环环系统；D为—CO—，CR2R3—，—CONH—，—NHCO—，—CR2（OH）—，—CONR2，NOR1CH—NO2N—CN—NR2—CO—，—C—，—C—，—C—；E为单键，可选择地取代的苯基，杂环；Z1为—（CH2）pW（CH2）q—，—O（CH2）pCR5R6—或—O（CH2）pW（CH2）q；G为—NR7R8，（a），（b），（c），一种含有5至12个碳原子的5-或6-成员饱和，不饱和或部分不饱和且可选择地取代的杂环或含有5至12个碳原子的双环胺，可以是桥接或融合的，并可选择地取代；R为卤素，—NR2R3，—NHCOR2，—NHSO2R2，—CR2R3OH，—CONR2R3，—SO2NR2R3，OH，—OR1，—OCOR1；是雌激素激动剂，可用于治疗由雌激素缺乏引起的综合征和疾病。

  公开号：

  US20030225100A1

文献信息

• Use of celivarone for the preparation of a medicament for use in the prevention of implantable cardioverter defibrillator interventions or death
  申请人：Sanofi-Aventis

  公开号：EP2308488A1

  公开（公告）日：2011-04-13

  The invention relates to the use of celivarone, or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for use in the prevention of Implantable Cardioverter Defibrillator interventions or death.

  本发明涉及使用西立伐龙或其药学上可接受的盐制备用于预防植入式心律转复除颤器介入或死亡的药物。
• AMINOALKYKBENZOYL-BENZOFURANES OU BENZOTHIOPHENES, LEUR PROCEDE DE PREPARATION ET LES COMPOSITIONS LES CONTENANT
  申请人：Sanofi-Aventis

  公开号：EP1315709B1

  公开（公告）日：2010-05-26
• STABLE NANOPARTICLE FORMULATIONS
  申请人：Sanofi-Aventis U.S. LLC

  公开号：EP1895982A2

  公开（公告）日：2008-03-12
• PHARMACEUTICAL COMPOSITION COMPRISING A SOLID DISPERSION WITH A POLYMER MATRIX CONTAINING A CONTINUOUS POLYDEXTROSE PHASE AND A CONTINUOUS PHASE OF A POLYMER OTHER THAN POLYDEXTROSE
  申请人：Bedos Michel

  公开号：US20070243257A1

  公开（公告）日：2007-10-18

  The present invention relates to a solid pharmaceutical composition comprising a solid dispersion containing at least one active principle and a pharmaceutically acceptable polymer matrix, a characterized in that said pharmaceutically acceptable polymer matrix comprises a blend of (i) polydextrose, in the form of a continuous polydextrose phase, in order to promote the disintegration of the composition in an aqueous medium, and (ii) at least one polymer other than polydextrose, in the form of a continuous phase of this polymer, whereby the polydextrose is in a concentration of at least 20 wt % and the at least one polymer other than polydextrose is in a concentration of at least 20 wt % in relation to the total weight of said pharmaceutically acceptable polymer matrix.
• Stable Nanoparticle Formulations
  申请人：ABU-IZZA Abdullah Khawla

  公开号：US20080038359A1

  公开（公告）日：2008-02-14

  The invention relates to pharmaceutically stable nanoparticle formulations of poorly soluble drug substances, to the processes for the preparation of such formulations, and to methods of use thereof.